Unmasking Silent Heart Failure in Diabetes: Insights from the TARTAN-HF Trial
Highlight
– Targeted screening using N-terminal pro-B-type natriuretic peptide (NT-proBNP) identifies a large proportion of previously unrecognized heart failure (HF) cases in high-risk diabetic patients.
– Most newly diagnosed HF cases in this population are heart failure with preserved ejection fraction (HFpEF).
– Screening led to increased use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), disease-modifying therapy with established cardiovascular benefits.
– The number needed to screen was only five to detect one new HF case, highlighting the clinical impact and feasibility of such strategies.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.